Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

about

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Item

http://www.wikidata.org/entity/Q48204106

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@en

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@nl

type

Item

label

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@en

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@nl

prefLabel

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@en

Aggressive lymphomas of the el ...... erapy schedule fits the unfit.

@nl

P1476

Aggressive lymphomas of the el ...... herapy schedule fits the unfit

@en

P2093

Agostino Tafuri

http://www.w3.org/2001/XMLSchema#string

Annalisa Arcari

http://www.w3.org/2001/XMLSchema#string

Francesca Fabbri

http://www.w3.org/2001/XMLSchema#string

Francesca di Landro

http://www.w3.org/2001/XMLSchema#string

Gerardo Musuraca

http://www.w3.org/2001/XMLSchema#string

Guido Bocci

http://www.w3.org/2001/XMLSchema#string

Ivana Casaroli

http://www.w3.org/2001/XMLSchema#string

Paola Anticoli-Borza

http://www.w3.org/2001/XMLSchema#string

Roberta Battistini

http://www.w3.org/2001/XMLSchema#string

Valerio Zoli

http://www.w3.org/2001/XMLSchema#string

P2860

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Metronomic chemotherapy: new rationale for new directions.

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin'

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

P304

819-822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.15039

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

183

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Merli

M Christina Cox

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29193017

http://www.w3.org/2001/XMLSchema#string